Presentation is loading. Please wait.

Presentation is loading. Please wait.

Intravenous Busulfan and Melphalan, Tacrolimus, and Short-Course Methotrexate Followed by Unmodified HLA-Matched Related or Unrelated Hematopoietic Stem.

Similar presentations


Presentation on theme: "Intravenous Busulfan and Melphalan, Tacrolimus, and Short-Course Methotrexate Followed by Unmodified HLA-Matched Related or Unrelated Hematopoietic Stem."— Presentation transcript:

1 Intravenous Busulfan and Melphalan, Tacrolimus, and Short-Course Methotrexate Followed by Unmodified HLA-Matched Related or Unrelated Hematopoietic Stem Cell Transplantation for the Treatment of Advanced Hematologic Malignancies  Trudy N. Small, James W. Young, Hugo Castro-Malaspina, Susan Prockop, Andrew Wilton, Glenn Heller, Farid Boulad, Michelle Chiu, Katherine Hsu, Ann Jakubowski, Nancy A. Kernan, Miguel-Angel Perales, Richard J. O’Reilly, Esperanza B. Papadopoulos  Biology of Blood and Marrow Transplantation  Volume 13, Issue 2, Pages (February 2007) DOI: /j.bbmt Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Cumulative incidence of recurrence.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 (A) OS and DFS (n = 43). (B) OS and DFS by blast count ≤ 20% or > 20%. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 OS (upper) and DFS (lower) in the 38 patients with a myeloid malignancy. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 Nonleukemic mortality.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions


Download ppt "Intravenous Busulfan and Melphalan, Tacrolimus, and Short-Course Methotrexate Followed by Unmodified HLA-Matched Related or Unrelated Hematopoietic Stem."

Similar presentations


Ads by Google